A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 2, 2000, Pages 229-234

  Manavathu, Elias K ^a   Cutright, Jessica L ^a   Loebenberg, David ^b   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DILUTION; DRUG STRUCTURE; FUNGICIDAL ACTIVITY; HUMAN; IN VITRO STUDY; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; TIME;

EID: 0033871689     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.2.229     Document Type: Article

References (28)

1. Novel analogs of SCH 51048: Synthesis and preliminary structure-activity relationships
2. SCH 56592, a novel broad spectrum antifungal agent
3. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
4. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
5. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
6. In vitro and in vivo efficacies of the azole Sch 56592 against Cryptococcus neoformans
7. Treatment of murine pulmonary blastomycosis with SCH 51048, a broad-spectrum triazole antifungal agent
8. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis
9. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
10. Treatment of Pneumocystis carinii with SCH 56592 in vitro and in vivo
11. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK 0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
12. Efficacy of prophylactic dosing of SCH 56592 against experimental pulmonary aspergillosis and systemic candidiasis in neutropenic mice
13. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
14. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
15. Activity of SCH 56592 (SCH), itraconazole (ITR) and amophotericin B (AMB) in experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (R. mackenziei (RO))
16. SCH 56592 (SCH) therapy of experimental murine cerebral phaeohyphomycosis due to Cladophialophora bantiana (CB)
17. In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus
18. Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent
19. A comparative study of the broth macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus
20. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
21. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
22. Organism-dependent fungicidal activities of azoles
23. Interaction of azole antifungal agents with cytochrome P-450(14DM) purified from Saccharomyces cerevisiae microsomes
24. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
25. In vitro activities of voriconazole (UK-109,496) and four other anti-fungal agents against 394 clinical isolates of Candida spp
26. Voriconazole against fluconazole-susceptible and -resistant Candida isolates: In-vitro efficacy compared with that of itraconazole and ketoconazole
27. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates